Floatz logo

Rasburicase

Untreated Childhood Acute Lymphoblastic Leukemia

Children's Oncology Groupprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

71 Active assets in the Untreated Childhood Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
MERCAPTOPURINE ANHYDROUS
Children's Oncology Group
Phase 3BBB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 3BBB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB

View all 50 →

Same molecule, other indications

Rasburicase is also rated in:

tumor lysis syndromeDormant
A
Indicative ·
80 / 100
View asset →
hematopoietic and lymphoid cell neoplasmDormant
BB
Indicative ·
67 / 100
View asset →
neoplasmDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →